SEC Form 4 · accession 0001203311-18-000020

SEATTLE GENETICS INC /WA · SGEN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — CMO & EVP, R & D

Period of report

Mar 20, 2018

Accepted (ET)

Mar 22, 2018 · 7:04 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001060736

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Mar 20, 2018	M	3,831	$26.10	A	174,765	D
Common Stock^F1	Mar 20, 2018	M	6,468	$15.46	A	181,233	D
Common Stock^F1	Mar 20, 2018	M	13,740	$12.00	A	194,973	D
Common Stock^F1	Mar 20, 2018	M	7,000	$10.61	A	201,973	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Incentive Stock Option (right to buy)^F2	$15.46	Mar 20, 2018	M	6,468	D	—	Aug 24, 2021	Common Stock	6,468	0	D
Incentive Stock Option (right to buy)^F3	$26.10	Mar 20, 2018	M	3,831	D	—	Aug 20, 2022	Common Stock	3,831	0	D
Non-Qualified Stock Option (right to buy)^F4	$10.61	Mar 20, 2018	M	7,000	D	—	May 7, 2020	Common Stock	7,000	0	D
Non-Qualified Stock Option (right to buy)^F5	$12.00	Mar 20, 2018	M	13,740	D	—	Aug 27, 2020	Common Stock	13,740	45,000	D

F1Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
F2Shares vested at a rate of 25% on 8/24/12 and monthly thereafter until all the shares were fully vested on 8/27/15.
F3Shares vested at a rate of 25% on 8/20/13 and monthly thereafter until all the shares were fully vested on 8/20/2016.
F4Shares vested at a rate of 25% on 5/7/11 and monthly thereafter until all the shares were fully vested on 5/7/14
F5Shares vested at a rate of 25% on 8/27/11 and monthly thereafter until all the shares were fully vested on 8/27/14.